Piramal Pharma Limited

Piramal Pharma Limited

Piramal Pharma Limited has informed the Exchange that the commercial arrangement with Bayer Pharmaceuticals Private Limited will expire on 31st December, 2026, and will not be renewed. The arrangement accounted for less than 5% of the company's consolidated revenue and is commission-based, with no material impact expected on profitability or financial position.

Piramal Pharma Limited

Piramal Pharma Limited clarifies recent news item about Ontario contributing $1.7 million investment to advance life sciences innovation at its Aurora facility. The funding support is not a material event, and the company's operations, financial position, or performance are not expected to be impacted.

Piramal Pharma Limited

Piramal Pharma Limited has announced the appointment of Mr. Viral Gandhi as Chief Technology Officer and Senior Management Personnel, effective October 1, 2026.

Piramal Pharma Limited

Piramal Pharma Limited has announced the retirement of Mr. Jeffrey Hampton, President and COO of Piramal Critical Care, and the appointment of Mr. Brian Guy as his successor, effective October 19, 2026.

Piramal Pharma Limited

The NSE has sought clarification from Piramal Pharma Limited regarding a recent news article about an investment in their Aurora facility.

Piramal Pharma Limited

Piramal Pharma Limited has informed the Exchange regarding the closure of the trading window for all Designated Persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the half year ending September 30, 2026.

Piramal Pharma Limited

Piramal Pharma Limited has received an order from the Additional Commissioner, CGST & Central Excise, Mumbai East Commissionerate, confirming a demand of Input Tax Credit (ITC) aggregating to Rs. 4,06,03,220/- along with applicable interest and imposing an equivalent penalty of Rs. 4,06,03,220/-.

Piramal Pharma Limited

Piramal Pharma Limited has been assigned an ESG rating of 67.1 (ESG Band: Leader) by Niche Ninety Nine Capability and Certifications (OPC) Private Limited, based on publicly available information.

Piramal Pharma Limited

Piramal Pharma Limited has informed that the US FDA conducted a Good Manufacturing Practices (GMP) inspection of its Morpeth, UK facility from September 3 to September 11, 2026. The FDA issued a Form-483 with 7 observations related to enhancement in practices, procedures, and documentation. The company is addressing these observations and will submit a detailed response within the stipulated timeline.

Piramal Pharma Limited

Piramal Pharma Limited has announced the schedule of Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Piramal Pharma Limited

Piramal Pharma Limited has received an ESG rating of 65 from NSE Sustainability Ratings and Analytics Limited for FY 2025-26, marking an improvement over the previous score of 64.

Piramal Pharma Limited

Piramal Pharma Limited has released its Sustainability Report for the financial year 2025-26, highlighting its progress in advancing innovation, leveraging sustainability, and addressing key sustainability pillars.

Piramal Pharma Limited

Piramal Pharma Limited has acquired an additional 40.67% stake in Yapan Bio Private Limited, increasing its shareholding from 33.33% to 74.00%. The acquisition was completed for an aggregate cash consideration of approximately ₹76 crores. Yapan has ceased to be an associate company and has become a subsidiary of Piramal Pharma Limited.

Piramal Pharma Limited

Piramal Pharma Limited has informed the Exchange regarding the exercise of a call option to acquire an additional 41% equity stake in Yapan Bio Private Limited, an associate company, from existing shareholders. The acquisition will increase the company's shareholding in Yapan from 33.33% to approximately 74%, making Yapan a subsidiary of Piramal Pharma Limited.

Piramal Pharma Limited

Piramal Pharma Limited has informed the stock exchanges about the schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meetings are scheduled to take place on various dates in September 2026 at different locations in India and Singapore.

Piramal Pharma Limited

Piramal Pharma Limited has resumed operations at its facilities in Ahmedabad, Gujarat, after a temporary suspension due to heavy rainfall and flooding. The company has completed a preliminary assessment and initiated the insurance claim process, with no material impact expected on its operations or financial performance.

Piramal Pharma Limited

Piramal Pharma Limited has informed the Exchange about the transcript of the Conference Call held on 30th July, 2026, on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June, 2026, available on the Company’s website.

Piramal Pharma Limited

Piramal Pharma Limited held its 6th Annual General Meeting on July 30, 2026, through video conferencing. The meeting was chaired by Ms. Nandini Piramal, and all resolutions proposed in the notice were passed with the requisite majority. The meeting was webcast live on the e-voting website of National Securities Depository Limited.

Piramal Pharma Limited

Piramal Pharma Limited has made available the audio recording of its conference call on unaudited financial results for the quarter ended 30th June, 2026, on its website.

Piramal Pharma Limited

Piramal Pharma Limited has announced its standalone and consolidated results for the First Quarter (Q1) ended 30th June 2026, with a 17% revenue growth, 72% EBITDA growth, and 12.5% EBITDA margin.